[{"address1": "650 Castro Street", "address2": "Suite 450", "city": "Mountain View", "state": "CA", "zip": "94041", "country": "United States", "phone": "650 200 0412", "website": "https://www.altoneuroscience.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD. The company was incorporated in 2019 and is headquartered in Mountain View, California.", "fullTimeEmployees": 76, "companyOfficers": [{"maxAge": 1, "name": "Dr. Amit  Etkin M.D., Ph.D.", "age": 47, "title": "Founder, Chairman of the Board, CEO & President", "yearBorn": 1977, "fiscalYear": 2024, "totalPay": 995998, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Nicholas C. Smith", "age": 35, "title": "CFO & Chief Business Officer", "yearBorn": 1989, "fiscalYear": 2024, "totalPay": 680467, "exercisedValue": 0, "unexercisedValue": 217377}, {"maxAge": 1, "name": "Mr. Michael C. Hanley M.B.A.", "age": 51, "title": "Chief Operating Officer", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 623006, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Dan  Segal B.Sc. (Hons), BCom, CA, MSc", "age": 62, "title": "Co-Founder & Strategic Advisor", "yearBorn": 1962, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Erin R. McQuade J.D.", "age": 49, "title": "General Counsel, Chief Administrative Officer & Corporate Secretary", "yearBorn": 1975, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Adam  Savitz M.D., Ph.D.", "age": 58, "title": "Chief Medical Officer", "yearBorn": 1966, "fiscalYear": 2024, "totalPay": 579569, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jessica  Powell", "age": 49, "title": "Chief Development Officer", "yearBorn": 1975, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 8, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1746057600, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 2.17, "open": 2.17, "dayLow": 2.15, "dayHigh": 2.3, "regularMarketPreviousClose": 2.17, "regularMarketOpen": 2.17, "regularMarketDayLow": 2.15, "regularMarketDayHigh": 2.3, "payoutRatio": 0.0, "forwardPE": -0.7700349, "volume": 94097, "regularMarketVolume": 94097, "averageVolume": 326552, "averageVolume10days": 182150, "averageDailyVolume10Day": 182150, "bid": 2.26, "ask": 2.3, "bidSize": 10, "askSize": 10, "marketCap": 59829344, "fiftyTwoWeekLow": 1.6, "fiftyTwoWeekHigh": 17.55, "fiftyDayAverage": 2.568, "twoHundredDayAverage": 6.3373, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -92538480, "profitMargins": 0.0, "floatShares": 19503574, "sharesOutstanding": 27072100, "sharesShort": 3269707, "sharesShortPriorMonth": 3761654, "sharesShortPreviousMonthDate": 1741910400, "dateShortInterest": 1744675200, "sharesPercentSharesOut": 0.120799996, "heldPercentInsiders": 0.07481, "heldPercentInstitutions": 0.82592005, "shortRatio": 10.13, "shortPercentOfFloat": 0.1533, "impliedSharesOutstanding": 27072100, "bookValue": 5.612, "priceToBook": 0.393799, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -61431000, "trailingEps": -2.5, "forwardEps": -2.87, "enterpriseToEbitda": 1.359, "52WeekChange": -0.85136986, "SandP52WeekChange": 0.08001411, "quoteType": "EQUITY", "currentPrice": 2.21, "targetHighPrice": 18.0, "targetLowPrice": 4.0, "targetMeanPrice": 12.33429, "targetMedianPrice": 10.0, "recommendationMean": 1.375, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 7, "totalCash": 168228992, "totalCashPerShare": 6.214, "ebitda": -68108000, "totalDebt": 16944000, "quickRatio": 16.809, "currentRatio": 16.92, "debtToEquity": 11.187, "returnOnAssets": -0.32465, "returnOnEquity": -0.55189997, "freeCashflow": -32294624, "operatingCashflow": -47424000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "ANRO", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "REGULAR", "shortName": "Alto Neuroscience, Inc.", "corporateActions": [], "regularMarketTime": 1746726465, "exchange": "NYQ", "messageBoardId": "finmb_1675972978", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketDayRange": "2.15 - 2.3", "fullExchangeName": "NYSE", "averageDailyVolume3Month": 326552, "fiftyTwoWeekLowChange": 0.61, "fiftyTwoWeekLowChangePercent": 0.38125, "fiftyTwoWeekRange": "1.6 - 17.55", "fiftyTwoWeekHighChange": -15.339999, "fiftyTwoWeekHighChangePercent": -0.87407404, "fiftyTwoWeekChangePercent": -85.136986, "epsTrailingTwelveMonths": -2.5, "epsForward": -2.87, "fiftyDayAverageChange": -0.35800004, "fiftyDayAverageChangePercent": -0.13940811, "twoHundredDayAverageChange": -4.1273, "twoHundredDayAverageChangePercent": -0.65127105, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.4 - Strong Buy", "regularMarketChangePercent": 1.8433162, "regularMarketPrice": 2.21, "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1706884200000, "regularMarketChange": 0.03999996, "displayName": "Alto Neuroscience", "trailingPegRatio": null, "__fetch_time": "2025-05-08"}]